ArticleThe oncologist2018
Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile.
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.BMC cancer · 2020Pooled it
- Optimal Treatments for NSCLC Patients Harboring Primary or AcquiredTechnology in cancer research & treatmentPooled it
- Trends in lung cancer incidence and stage at diagnosis in Singapore: a population-based joinpoint regression analysis by age, sex, and smoking status.The Lancet regional health. Western Pacific · 2026Article
- HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules.World journal of surgical oncology · 2025Article
- EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass Opacities.Annals of surgical oncology · 2025Article
- Lung cancer in young individuals; risk factors and epidemiology.Journal of thoracic disease · 2025Review
- Comprehensive characterization of early-onset lung cancer, in Chinese young adults.Nature communications · 2025Article
- Improving diagnostic capabilities in lung cancer through next-generation sequencing: a narrative review.Journal of thoracic disease · 2025Review
- Early-onset lung cancer in Asia: a narrative review.Frontiers in oncology · 2025Review
- A profile of lung cancer in the young population with a highlight on the Indian perspective.Frontiers in oncology · 2025Review
- Young lung cancer: from diagnosis to survivorship.Frontiers in oncology · 2025Review
- Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.Frontiers in immunology · 2024Article
- Driver and actionable mutations in younger patients with lung cancer - are we searching properly?Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2023Article
- Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.Journal of translational medicine · 2023Review
- Clinicopathological characteristics and prognosis of young patients aged ≤45 years old with non-small cell lung cancer.Open medicine (Warsaw, Poland) · 2023Article
- [Research Progress of Treatment for NSCLC in Young Patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma.Journal of Cancer · 2022Article
- Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.Journal of clinical laboratory analysis · 2021Article
- Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOccurrence at a younger age has been demonstrated to be associated with a distinct biology in non-small cell lung cancer. However, genomics and clinical characteristics among younger patients with lung adenocarcinoma remain to be determined. Here we studied the potentially targetable genetic alterations by next-generation sequencing (NGS) assay in young Chinese patients with lung adenocarcinoma. MATERIALS AND
methodsSeventy-one surgically resected lung adenocarcinoma tissue samples from patients aged less than 45 years were collected with informed consent from all patients. Targeted NGS assays were used to identify actionable genetic alterations in the cancer tissues. Additionally, the genomic and clinicopathologic characteristics of 106 patients with lung adenocarcinoma who received NGS testing over the same period were analyzed retrospectively.
resultsThe frequencies of targetable genetic alterations in 177 patients with lung adenocarcinoma were analyzed by defined age categories, which unveiled a distinctive molecular profile in the younger group, aged less than 45 years. Notably, higher frequency of
conclusionIn this study, NGS assay revealed a distinctive genetic profile in younger patients with adenocarcinoma. High frequency of concurrent IMPLICATIONS FOR PRACTICE: Further investigation is needed to understand the genomics and clinical characteristics of young patients with lung adenocarcinoma. In the present study, hybrid capture-based next-generation sequencing assays were used to identify targeted genetic alterations in young lung adenocarcinoma patients. Young patients with lung adenocarcinoma, aged less than 45 years, harbored a higher frequency of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.